ABSTRACT
Despite treatment with praziquantel (PZQ) at 40 mg/kg in food, several chimpanzees on Ngamba Island Chimpanzee Sanctuary (NICS) continue to excrete eggs of Schistosoma mansoni. To monitor disease, 8 animals were closely examined under anaesthesia in March 2011 with portable ultrasonography and by rectal snip biopsy. Schistosome genetic diversity had been previously assayed within 4 of these chimpanzees, finding extensive diversity with 27 DNA barcodes encountered, although none was common to all animals. Calcified schistosome eggs were found in the rectal snips from 5 chimpanzees and liver fibrosis was clearly documented, indicative of progressive disease in 6 animals, the latter being surprisingly advanced in a younger chimpanzee. All 8 animals were treated under anaesthesia by oral gavage with PZQ at 60 mg/kg dosing that was well tolerated. These animals were again re-examined in June 2012 using stool and urine sampling. Only 1 chimpanzee appeared to be free from infection and active egg excretion was confirmed in 6 animals. If intestinal schistosomiasis is to be controlled within this setting, a long-term disease management plan is required which should combine active case-detection with an insistent treatment regime with praziquantel for these chimpanzees, exploring perhaps the performance of even higher dosing.
Subject(s)
Ape Diseases/parasitology , Genetic Variation , Liver Cirrhosis/veterinary , Schistosoma mansoni/drug effects , Schistosoma mansoni/genetics , Schistosomiasis mansoni/veterinary , Animals , Anthelmintics/administration & dosage , Anthelmintics/therapeutic use , Ape Diseases/diagnostic imaging , Ape Diseases/drug therapy , DNA Barcoding, Taxonomic , Feces/parasitology , Female , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/drug therapy , Liver Cirrhosis/parasitology , Male , Pan troglodytes , Parasite Egg Count , Praziquantel/administration & dosage , Praziquantel/therapeutic use , Schistosoma mansoni/isolation & purification , Schistosomiasis mansoni/diagnostic imaging , Schistosomiasis mansoni/drug therapy , Schistosomiasis mansoni/parasitology , Treatment Outcome , Uganda , Ultrasonography , Urine/parasitologyABSTRACT
Schistosomiasis is one of the world's most widely distributed and prevalent parasitic diseases. Less widely recognized is that some species of Schistosoma, including several that commonly affect humans, also cause disease in other mammalian species; in particular, infections in non-human primates are known. With interest increasing in emerging zoonotic diseases, the status of schistosomiasis as a zoonotic infection is in need of re-appraisal, especially in light of advances in application of molecular screening and epidemiological tools where newly reported infections raise general animal welfare and conservation concerns. Focusing on Africa, this review provides a summary of the occurrence of schistosomiasis in non-human primates and discusses new ways in which surveillance for schistosomiasis should be integrated into more effective conservation management and disease control strategies. Emphasis is on the more common forms of human schistosomiasis, their clinical manifestations and epidemiological significance in terms of infection reservoir potential.
Subject(s)
Primate Diseases/epidemiology , Primate Diseases/parasitology , Schistosoma/isolation & purification , Schistosomiasis/veterinary , Zoonoses/epidemiology , Zoonoses/parasitology , Africa/epidemiology , Animals , Humans , Prevalence , Primates , Schistosomiasis/epidemiology , Schistosomiasis/parasitologyABSTRACT
BACKGROUND: To understand immunological responses in chimpanzees vaccinated with live-attenuated vaccine (oral polio vaccine; OPV), serum neutralizing antibodies against poliovirus types 1, 2, and 3 were investigated over time. METHODS: The neutralizing antibody titers against poliovirus types 1, 2, and 3 were determined by microneutralization test using 100 ID(50) of poliovirus types 1, 2, and 3 (Sabin strains). RESULTS: Neutralizing antibodies against poliovirus types 1, 2, and 3 were detected in 85.7%, 71.4%, and 65% of the serum from 42 chimpanzees tested 9 years post-vaccination. The neutralizing antibody titers in chimpanzees were similar to the documented levels in human studies as an indicator of vaccine efficacy. CONCLUSIONS: This study reveals persistence of neutralizing antibodies in chimpanzees for at least 9 years after vaccination with OPV. This first study in chimpanzees provides useful information for the evaluation of the success of vaccination with OPV in other captive apes.
Subject(s)
Ape Diseases/prevention & control , Pan troglodytes/immunology , Poliomyelitis/veterinary , Poliovirus Vaccine, Oral/immunology , Poliovirus/immunology , Vaccination/veterinary , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Ape Diseases/immunology , Ape Diseases/virology , Female , Male , Neutralization Tests/veterinary , Poliomyelitis/immunology , Poliomyelitis/prevention & control , Poliomyelitis/virology , Poliovirus Vaccine, Oral/administration & dosage , UgandaABSTRACT
BACKGROUND: Recent studies in non-human primates have led to the discovery of novel primate herpesviruses. In order to get more information on herpesvirus infections in apes, we studied wild born captive chimpanzees. METHODS: Chimpanzees of the Ngamba island sanctuary, Uganda, were analyzed with pan-herpes polymerase chain reaction (PCR) targeting the herpesvirus DNA polymerase gene and the glycoprotein B gene. The obtained sequences were connected by long-distance PCR, and analyzed phylogenetically. RESULTS: Twenty-one of 40 individuals were infected with members of the Gammaherpesvirinae, two of them with a novel member of this subfamily. Phylogenetically, the novel virus fell into a clade of primate rhadinoviruses and the Kaposi sarcoma herpesvirus (human herpesvirus 8), representing a third distinct rhadinovirus in chimpanzees. CONCLUSION: Non-human primates harbor several herpesviruses many of which are still unknown. This has implications to management of primates in sanctuaries requiring continuous updates on the management protocols to deal with potential occupational pathogens.